Key result
Transplacental maternal administration of oral digoxin successfully reduced fetal heart rate from 204-220 bpm to 139-156 bpm within 7 days, maintaining sinus rhythm until delivery.
Why the study?
Fetal supraventricular tachycardia is the most common primary fetal tachycardia and can cause non-immune hydrops, significant perinatal morbidity, and mortality.
Case Report (n=1)
No
Transplacental maternal oral digoxin successfully treated fetal supraventricular tachycardia, restoring normal sinus rhythm without adverse neonatal outcomes.
Answers are grounded in this paper and cite their sources.
Maternal oral digoxin may offer a viable transplacental treatment for fetal SVT; leaves open the.
Fetal supraventricular tachycardia (SVT) is the most common form of primary fetal tachycardia. It is a known cause of non-immune hydrops and can lead to significant perinatal morbidity and mortality. We report a case of a 27-year-old primigravida with a diagnosis of fetal supraventricular tachycardia. Her fetus was treated transplacentally with maternal oral digoxin leading to reversion to sinus rhythm. She was delivered by caesarean section and baby had an uneventful neonatal period.
No takes yet. Share an insight, caveat, or question.
Ezeama et al. (2023) conducted a case report in Fetal supraventricular tachycardia (n=1). Transplacental digoxin was evaluated on Fetal heart rate and reversion to sinus rhythm. Transplacental maternal administration of oral digoxin successfully reduced fetal heart rate from 204-220 bpm to 139-156 bpm within 7 days, maintaining sinus rhythm until delivery.
Synapse has enriched 10 related papers. Consider them for comparative context: